Antares Pharma (NASDAQ:ATRS) Earns Media Impact Rating of -0.35
News coverage about Antares Pharma (NASDAQ:ATRS) has trended negative this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Antares Pharma earned a news sentiment score of -0.35 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 66 out of 100, indicating that recent press coverage is likely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- Shares Running on Volume: Vanstar Mining Resources Inc (VSR.V) – Evergreen Caller (evergreencaller.com)
- Antares Pharma to Report Second Quarter 2017 Financial and Operating Results and Host Webcast and Conference Call – GlobeNewswire (press release) (globenewswire.com)
- Weekly Snap of Healthcare stock: Antares Pharma, Inc. (ATRS) stock moved 3.64% up – Street Observer (press release) (streetobserver.com)
- Antares Pharma Inc (ATRS) AO Trending Down This Week – FLBC News (flbcnews.com)
Several research analysts recently issued reports on ATRS shares. Vetr upgraded shares of Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 target price for the company in a research report on Monday, July 24th. Piper Jaffray Companies set a $4.00 target price on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Antares Pharma in a research report on Friday, June 23rd. Chardan Capital started coverage on shares of Antares Pharma in a research report on Friday, June 23rd. They issued a “buy” rating and a $5.00 target price for the company. Finally, Raymond James Financial, Inc. started coverage on shares of Antares Pharma in a research report on Thursday, April 20th. They issued a “strong-buy” rating and a $4.30 target price for the company. One analyst has rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $3.83.
Shares of Antares Pharma (NASDAQ:ATRS) traded up 2.30% during trading on Friday, hitting $3.12. 869,310 shares of the stock traded hands. The firm’s 50-day moving average price is $3.12 and its 200-day moving average price is $2.73. The stock’s market cap is $486.49 million. Antares Pharma has a 12 month low of $1.01 and a 12 month high of $3.37.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. Antares Pharma had a negative net margin of 41.26% and a negative return on equity of 45.05%. The company had revenue of $12.01 million for the quarter, compared to analysts’ expectations of $12.10 million. Analysts anticipate that Antares Pharma will post ($0.13) EPS for the current year.
In other Antares Pharma news, insider Fred M. Powell bought 130,000 shares of the stock in a transaction dated Friday, June 9th. The shares were acquired at an average cost of $2.79 per share, for a total transaction of $362,700.00. Following the completion of the transaction, the insider now owns 331,434 shares in the company, valued at approximately $924,700.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 11.60% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.